Project Description

Infectious diseases are still among the top ten causes of death worldwide. The most relevant factor accounting for the high incidence of infectious diseases is the spread of strains resistant to multiple drugs (MDR), which is leaving clinicians with very limited options to treat certain infections. This is especially serious for Gram-negative pathogens since they are intrinsically resistant to many antibiotics due to their complex cell envelope. The bacterial cell envelope has been and still remains one of the best targets for antimicrobials development and to overcome antimicrobial resistance (AMR). Train2Target proposes a novel approach to tackling AMR by exploring the envelope structure and its biogenesis. This will help deliver new leads for the antibacterials discovery and development programmes of our biotech and pharma partners.

Abstract

The alarming threats and spread of multi-drug resistant bacteria is currently leaving clinicians with very limited options to combat infections especially those from Gram-negative pathogens. Train2Target is a multidisciplinary European Training Network built to address the challenge of the discovery of alternative antimicrobials. It also represents a unique research platform to train 15 Early Stage Researchers and equip them with the necessary scientific and transferable skills to develop innovative strategies and research to deliver a next generation of drugs.
The Train 2Target research programme focuses on the assembly of the well-known bacterial cell envelope from a new perspective. Indeed it aims to inhibit novel targets in envelope biogenesis by altering the function and misbalancing the coordination of envelope assembly machines, which build and assemble the Gram-negative bacterial envelope. A wide variety of chemical classes and compounds sources will be screened using innovative biochemical, biophysical and genetic assays to identify valuable hit scaffolds to be optimised into druggable leads.
The high quality and credibility of the Train2Target consortium is ensured by a strong interdisciplinary academia-industry partnership to encompass different complementary expertise. This unique combination of scientific excellence and industrial know-how in drug discovery covers the entire process from the design to the implementation of innovative antibacterial strategies and lead identification for the benefit of Europe`s biotech and pharma industries, as well as for the health of societies in Europe and beyond.

 

Our Role

accelopment is a Partner Organisation in Train2Target. We are involved in three areas of the project – assisting in project management tasks, coordinating the communication and dissemination activities and contributing to the ESR training activities with two courses on Communication & Organisation and Funding & Career.

Project Details

Coordinator: 
Università degli Studi di Milano, IT
Partners: 
Università degli Studi di Milano
Centre Nationale de la Recherche Scientifique
Newcastle University upon Tyne
Université catholique de Louvain
Universiteit van Amsterdam
The University of Birmingham
Università degli Studi di Napoli Federico II.
AiCuris GmbH
AntibioTx Aps
BioVersys AG
Naicons Srl
accelopment AG (Partner Organisation)
Contact: 
Duration: 
01.01.2017 – 31.12.2020
Budget: 
3.6 million euro
Our Services: 
Proposal Writing
Contract Negotiations
Project Management
Project Dissemination
Funding Programme: 
  • H2020-MSCA-ITN
Area: 
Lifesciences

Testimonial

Prof Alessandra Polissi, University of Milano, IT

The preparation of a Horizon 2020 proposal extends beyond technical knowledge and requires great experience and organization skills. accelopment has been an invaluable partner in the drafting of the Train2Target proposal and its longtime experience will be essential for achieving our objectives.

Prof Alessandra Polissi, University of Milano, IT